02:01 , Sep 29, 2018 |  BioCentury  |  Politics, Policy & Law

PROs in prime time

A recommendation by CMS’s MEDCAC catapults the collection of PRO data to the postmarket setting from their more familiar spot in clinical development. CAR T leaders Novartis AG and Gilead Sciences Inc., however, are not...
22:45 , Apr 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest CAR T cells targeting GD2 could help treat diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas harboring the H3.3A K27M mutation. In co-culture with...
21:54 , Apr 16, 2018 |  BC Extra  |  Preclinical News

Anti-GD2 CAR T could treat midline gliomas

A study published in Nature Medicine suggests that CAR T cells targeting ganglioside GD2 could help treat diffuse midline gliomas with mutated histone H3 K27M. GD2 has been identified as a target to treat cancers...
21:06 , Sep 21, 2017 |  BC Innovations  |  Translation in Brief

Driving CARs into neuroblastoma

In separate studies published in the same July issue of the Proceedings of the National Academies of Sciences , NCI and Karolinska Institute teams each discovered a new target for high-risk forms of neuroblastoma. The...
20:28 , Aug 11, 2017 |  BC Week In Review  |  Company News

Sinobioway provides update on its bid to acquire Sinovac

A consortium led by Shandong Sinobioway Biomedicine Co. Ltd. (SZSE:002581) said it submitted all required documents to Sinovac Biotech Ltd. (NASDAQ:SVA) to prove it has sufficient funds to finance an $8 per share bid to...
20:46 , Jul 7, 2017 |  BC Week In Review  |  Company News

Sinovac going private

Sinovac Biotech Ltd. (NASDAQ:SVA) said it will be acquired by an investor syndicate led by Chairman, President and CEO Weidong Yin and SAIF Partners for $7 per share, or about $401.8 million. Other investors include...
20:55 , Jul 3, 2017 |  BC Extra  |  Company News

Sinobioway counters Sinovac buyout offer

A consortium led by Shandong Sinobioway Biomedicine Co. Ltd. (SZSE:002581) has entered a counteroffer to acquire Sinovac Biotech Ltd. (NASDAQ:SVA), which said last week an investor syndicate led by its Chairman, President and CEO Weidong...
20:30 , Jun 26, 2017 |  BC Extra  |  Financial News

Sinovac going private

Sinovac Biotech Ltd. (NASDAQ:SVA) said it will be acquired by an investor syndicate led by Chairman, President and CEO Weidong Yin and SAIF Partners for $7 per share, or about $401.8 million. Other investors include...
20:23 , May 26, 2017 |  BC Week In Review  |  Company News

BioAtla, Beijing Sinobioway expand CAB deal

BioAtla LLC (San Diego, Calif.) and Beijing Sinobioway Group Ltd. (Beijing, China) added five products from BioAtla's Conditionally Active Biologic (CAB) platform to a 2015 deal granting Sinobioway exclusive rights to develop and commercialize similar...
22:33 , Jan 6, 2017 |  BC Week In Review  |  Financial News

F1 Oncology completes venture financing

F1 Oncology raised $37 million in a series A round from F1 BioVentures, Sinobioway Group and SunTerra Capital. F1 Oncology Inc. , West Palm Beach, Fla. ...